# Ideal Power Inc.: financial statements, quarterly

IPWR · Nasdaq · CIK 1507957 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ipwr.md) · [Financials](/companies/ipwr/financials.md) · [Filings](/companies/ipwr/filings.md) · [Insiders](/companies/ipwr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ipwr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [1.6](/filings/0001437749-24-035091.md) | [61.5 d](/filings/0001437749-25-009911.md) | [78.7](/filings/0001437749-25-017025.md) | [1.3](/filings/0001437749-25-026716.md) | [0.6](/filings/0001437749-25-034655.md) | [5.4 d](/filings/0001437749-26-009995.md) | [12.0](/filings/0001437749-26-017430.md) | [1.3](/filings/0001437749-26-027661.md) | [24.5](/filings/0001437749-25-034655.md) | [0.0 d](/filings/0001437749-26-009995.md) | [0.0](/filings/0001437749-26-017430.md) | [5.8](/filings/0001437749-26-027661.md) |
| Cost of revenue | $k | [2.8](/filings/0001437749-24-035091.md) | [46.4 d](/filings/0001437749-25-009911.md) | [68.5](/filings/0001437749-25-017025.md) | [17.5](/filings/0001437749-25-026716.md) | [1.5](/filings/0001437749-25-034655.md) | [5.9 d](/filings/0001437749-26-009995.md) | [30.9](/filings/0001437749-26-017430.md) | [3.5](/filings/0001437749-26-027661.md) | [26.1](/filings/0001437749-25-034655.md) | [0.0 d](/filings/0001437749-26-009995.md) | [0.0](/filings/0001437749-26-017430.md) | [4.0](/filings/0001437749-26-027661.md) |
| Gross profit | $k | [(1.2)](/filings/0001437749-24-035091.md) | [15.1 d](/filings/0001437749-25-009911.md) | [10.2](/filings/0001437749-25-017025.md) | [(16.1)](/filings/0001437749-25-026716.md) | [(1.0)](/filings/0001437749-25-034655.md) | [(0.5) d](/filings/0001437749-26-009995.md) | [(18.9)](/filings/0001437749-26-017430.md) | [(2.2)](/filings/0001437749-26-027661.md) | [(1.6)](/filings/0001437749-25-034655.md) | [0.0 d](/filings/0001437749-26-009995.md) | [0.0](/filings/0001437749-26-017430.md) | [1.8](/filings/0001437749-26-027661.md) |
| Research and development | $k | [1,691](/filings/0001437749-24-035091.md) | [1,406 d](/filings/0001437749-25-009911.md) | [1,367](/filings/0001437749-25-017025.md) | [1,563](/filings/0001437749-25-026716.md) | [1,684](/filings/0001437749-25-034655.md) | [1,594 d](/filings/0001437749-26-009995.md) | [1,568](/filings/0001437749-26-017430.md) | [1,900](/filings/0001437749-26-027661.md) | [1,793](/filings/0001437749-25-034655.md) | [786 d](/filings/0001437749-26-009995.md) | [2,032](/filings/0001437749-26-017430.md) | [1,430](/filings/0001437749-26-027661.md) |
| Operating income | $k | [(2,840)](/filings/0001437749-24-035091.md) | [(2,485) d](/filings/0001437749-25-009911.md) | [(2,527)](/filings/0001437749-25-017025.md) | [(2,886)](/filings/0001437749-25-026716.md) | [(2,900)](/filings/0001437749-25-034655.md) | [(2,759) d](/filings/0001437749-26-009995.md) | [(2,825)](/filings/0001437749-26-017430.md) | [(3,140)](/filings/0001437749-26-027661.md) | [(3,020)](/filings/0001437749-25-034655.md) | [(1,948) d](/filings/0001437749-26-009995.md) | [(3,692)](/filings/0001437749-26-017430.md) | [(3,623)](/filings/0001437749-26-027661.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(2,740)](/filings/0001437749-24-035091.md) | [(2,406) d](/filings/0001437749-25-009911.md) | [(2,470)](/filings/0001437749-25-034655.md) | [(2,662)](/filings/0001437749-25-034655.md) | [(2,690)](/filings/0001437749-25-034655.md) | [(2,596) d](/filings/0001437749-26-009995.md) | [(2,703)](/filings/0001437749-26-027661.md) | [(3,037)](/filings/0001437749-26-027661.md) | [(2,941)](/filings/0001437749-25-034655.md) | [(1,898) d](/filings/0001437749-26-009995.md) | [(3,632)](/filings/0001437749-26-027661.md) | [(3,413)](/filings/0001437749-26-027661.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(0.44)](/filings/0001437749-24-035091.md) | not reported | [(0.39)](/filings/0001437749-25-017025.md) | [(0.31)](/filings/0001437749-25-026716.md) | [(0.31)](/filings/0001437749-25-034655.md) | not reported | [(0.30)](/filings/0001437749-26-017430.md) | [(0.33)](/filings/0001437749-26-027661.md) | [(0.32)](/filings/0001437749-25-034655.md) | not reported | [(0.33)](/filings/0001437749-26-017430.md) | [(0.20)](/filings/0001437749-26-027661.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: not reported
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [10.8](/filings/0001437749-23-031954.md) | [8.5](/filings/0001437749-25-009911.md) | [20.2](/filings/0001437749-24-016893.md) | [20.1](/filings/0001437749-24-026596.md) | [18.7](/filings/0001437749-24-035091.md) | [15.8](/filings/0001437749-26-009995.md) | [13.7](/filings/0001437749-25-017025.md) | [11.1](/filings/0001437749-25-026716.md) | [8.4](/filings/0001437749-25-034655.md) | [6.1](/filings/0001437749-26-027661.md) | [16.4](/filings/0001437749-26-017430.md) | [41.3](/filings/0001437749-26-027661.md) |
| Current assets | $m | [11.2](/filings/0001437749-23-031954.md) | [9.1](/filings/0001437749-25-009911.md) | [20.8](/filings/0001437749-24-016893.md) | [20.5](/filings/0001437749-24-026596.md) | [19.0](/filings/0001437749-24-035091.md) | [16.3](/filings/0001437749-26-009995.md) | [14.1](/filings/0001437749-25-017025.md) | [11.4](/filings/0001437749-25-026716.md) | [8.7](/filings/0001437749-25-034655.md) | [6.5](/filings/0001437749-26-027661.md) | [16.8](/filings/0001437749-26-017430.md) | [41.6](/filings/0001437749-26-027661.md) |
| Total assets | $m | [14.4](/filings/0001437749-23-031954.md) | [12.2](/filings/0001437749-25-009911.md) | [23.9](/filings/0001437749-24-016893.md) | [23.4](/filings/0001437749-24-026596.md) | [22.6](/filings/0001437749-24-035091.md) | [19.8](/filings/0001437749-26-009995.md) | [17.6](/filings/0001437749-25-017025.md) | [14.9](/filings/0001437749-25-026716.md) | [12.2](/filings/0001437749-25-034655.md) | [10.0](/filings/0001437749-26-027661.md) | [20.5](/filings/0001437749-26-017430.md) | [45.0](/filings/0001437749-26-027661.md) |
| Current liabilities | $m | [0.8](/filings/0001437749-23-031954.md) | [0.9](/filings/0001437749-25-009911.md) | [1.0](/filings/0001437749-24-016893.md) | [0.9](/filings/0001437749-24-026596.md) | [0.9](/filings/0001437749-24-035091.md) | [0.6](/filings/0001437749-26-009995.md) | [0.7](/filings/0001437749-25-017025.md) | [0.9](/filings/0001437749-25-026716.md) | [0.9](/filings/0001437749-25-034655.md) | [1.0](/filings/0001437749-26-027661.md) | [1.5](/filings/0001437749-26-017430.md) | [1.5](/filings/0001437749-26-027661.md) |
| Total liabilities | $m | [2.1](/filings/0001437749-23-031954.md) | [2.2](/filings/0001437749-25-009911.md) | [2.2](/filings/0001437749-24-016893.md) | [1.9](/filings/0001437749-24-026596.md) | [2.4](/filings/0001437749-24-035091.md) | [2.0](/filings/0001437749-26-009995.md) | [2.1](/filings/0001437749-25-017025.md) | [2.2](/filings/0001437749-25-026716.md) | [2.2](/filings/0001437749-25-034655.md) | [2.2](/filings/0001437749-26-027661.md) | [2.7](/filings/0001437749-26-017430.md) | [2.6](/filings/0001437749-26-027661.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [12.2](/filings/0001437749-24-035091.md) | [10.1](/filings/0001437749-26-009995.md) | [21.7](/filings/0001437749-25-034655.md) | [21.5](/filings/0001437749-25-034655.md) | [20.2](/filings/0001437749-25-034655.md) | [17.9](/filings/0001437749-26-027661.md) | [15.5](/filings/0001437749-26-027661.md) | [12.7](/filings/0001437749-26-027661.md) | [10.1](/filings/0001437749-25-034655.md) | [7.9](/filings/0001437749-26-027661.md) | [17.8](/filings/0001437749-26-027661.md) | [42.5](/filings/0001437749-26-027661.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,770) d](/filings/0001437749-24-035091.md) | [(1,953) d](/filings/0001437749-25-009911.md) | [(1,875)](/filings/0001437749-25-017025.md) | [(2,096) d](/filings/0001437749-25-026716.md) | [(2,222) d](/filings/0001437749-25-034655.md) | [(2,550) d](/filings/0001437749-26-009995.md) | [(2,067)](/filings/0001437749-26-017430.md) | [(2,359) d](/filings/0001437749-26-027661.md) | [(2,548) d](/filings/0001437749-25-034655.md) | [(2,162) d](/filings/0001437749-26-009995.md) | [(2,035)](/filings/0001437749-26-017430.md) | [(2,438) d](/filings/0001437749-26-027661.md) |
| Capital expenditure | $k | [84.3 d](/filings/0001437749-24-035091.md) | [42.5 d](/filings/0001437749-25-009911.md) | [29.6](/filings/0001437749-25-017025.md) | [34.4 d](/filings/0001437749-25-026716.md) | [129 d](/filings/0001437749-25-034655.md) | [3.8 d](/filings/0001437749-26-009995.md) | [11.3](/filings/0001437749-26-017430.md) | [29.8 d](/filings/0001437749-26-027661.md) | [70.2 d](/filings/0001437749-25-034655.md) | [8.1 d](/filings/0001437749-26-009995.md) | [142](/filings/0001437749-26-017430.md) | [9.6 d](/filings/0001437749-26-027661.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2020 (2020-09-30) | Q1 FY2021 (2021-03-31) | Q2 FY2021 (2021-06-30) | Q3 FY2021 (2021-09-30) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [3,822](/filings/0001104659-21-137527.md) | [5,344](/filings/0001104659-22-061311.md) | [6,126](/filings/0001104659-22-091273.md) | [6,126](/filings/0001104659-22-118578.md) | [6,155](/filings/0001104659-23-059376.md) | [6,158](/filings/0001104659-23-089993.md) | [6,158](/filings/0001104659-22-118578.md) | [6,179](/filings/0001104659-23-059376.md) | [6,185](/filings/0001104659-23-089993.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 16,434,655 at 2026-08-11, from the cover of the [10-Q filed 2026-08-13](/filings/0001437749-26-027661.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.